Immunocore Holdings Ltd (IMCR) — Capital Reinvestment Ratio

Latest as of June 2025: 0.02x

Immunocore Holdings Ltd (IMCR) has a Capital Reinvestment Ratio of 0.02x as of June 2025, meaning it reinvests 0% of its operating cash flow ($25.96 Million) in capital expenditures ($414.00K). See Immunocore Holdings Ltd net asset quality index to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.02x
Capex / Operating Cash Flow

Operating Cash Flow

$25.96 Million
USD

Capital Expenditures

$414.00K
USD

Data as of

Jun 2025
Most recent filing

Immunocore Holdings Ltd Capital Reinvestment Ratio (2023–2024)

This chart tracks Immunocore Holdings Ltd's Capital Reinvestment Ratio across 2 annual periods. Check total reinvestment intensity of Immunocore Holdings Ltd to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Immunocore Holdings Ltd (2023–2024)

Year-by-year Capital Reinvestment Ratio for Immunocore Holdings Ltd from 2023 to 2024. For live market cap and broader valuation context, see market value of Immunocore Holdings Ltd.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2024 0.20x $26.06 Million $5.17 Million ▼ -89.2%
2023 1.85x $2.94 Million $5.42 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow